Clineage
Launch clinical studies
Archived App (Last seen on 12 May 2026)
This is an archived listing of the app previously available on the App Store.Although the app is no longer distributed by Apple, you can still view its description, screenshots, version history, ratings, and metadata for reference.
About
Design, build, and launch clinical studies directly to the app store. This tool streamlines the process, reducing engineering time from months to days. Customize functionality and access your specific study data.
What's New in Clineage
3.6.1
February 21, 2024
- small bug fix
FAQ
How does Clineage reduce the time to launch clinical studies?
Clineage allows sponsors and researchers to design, build, and launch studies directly to the app store. This process, which previously took months of engineering work, can now be completed in days.
Can I customize the functionality of my clinical studies with Clineage?
Yes, users can customize what functionality and capability are required for each of their unique studies. This ensures that the application meets the specific needs of your research.
What kind of data can I access through Clineage?
Clineage enables access to a sponsor or researcher’s specific repository of studies and data. This provides a centralized location for all your research-related information.
What devices does Clineage support?
Clineage currently supports iPads. This allows for a focused and optimized experience on tablet devices.
How often is Clineage updated?
The latest version of Clineage is 3.6.1, and it was last updated on February 21, 2024. Updates aim to improve functionality and reliability.
What is the age rating for Clineage?
Clineage has an age rating of 4+. This indicates it is suitable for a wide range of users.
Does Clineage have ads?
No, Clineage does not contain advertisements. The application is free to use without any ad interruptions.
What is the user rating for Clineage?
Clineage has a perfect rating of 5.0 stars from 1 rating. This suggests a highly positive user experience from its initial reviews.
